World's Best Scientists 2026 revealed!
Drug Discovery Today
H-index 54

Drug Discovery Today

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 594 86 104 32

Additional Metrics

Number of Best Scientists*: 399
Documents by Best Scientists*: 462
Top 100 Ranked Scientists*: 12
SCIMAGO H-index: 226
SCIMAGO SJR: 1.742
Impact Factor: 7.5

Overview

Top Research Topics at Drug Discovery Today?

The journal investigates areas of study like Drug discovery, Pharmacology, Computational biology, Drug and Nanotechnology. Drug discovery research presented in Drug Discovery Today encompasses a variety of subjects, including Pharmaceutical sciences, Drug development, Data science and Pharmaceutical technology. Discussions in the journal are anchored in the subject of Computational biology and the similar topic of Genomics.

Nanotechnology works presented in the journal have a specific focus on Drug delivery.

  • Drug discovery (32.46%)
  • Pharmacology (17.22%)
  • Computational biology (14.89%)

What are the most cited papers published in the journal?

  • The growing impact of click chemistry on drug discovery. (2557 citations)
  • PEGylation, successful approach to drug delivery. (1815 citations)
  • Peptide therapeutics: current status and future directions. (1507 citations)

Research areas of the most cited articles at Drug Discovery Today:

The main points discussed in the most cited papers deal with Drug discovery, Pharmacology, Pharmaceutical technology, Computational biology and Nanotechnology. The published papers focus on Drug discovery but the discussions also offer insight into other areas such as Pharmaceutical sciences, Drug development and Pharmaceutical industry. The most cited publications explore issues in Pharmacology which can be linked to other research areas like Receptor, Drug delivery and In vivo.

What topics the last edition of the journal is best known for?

  • Gene
  • Internal medicine
  • Cancer

The previous edition focused in particular on these issues:

The journal mainly tackles studies in Drug discovery, Cancer research, Drug, Computational biology and Drug development. The Drug discovery study featured in the journal draws connections with the study of Data science. In Drug Discovery Today, Cancer cell, Cancer, Receptor and Immune system are investigated in conjunction with one another to address concerns in Cancer research research.

Drug research discussed connects with the study of Intensive care medicine. The journal links adjacent topics like Intensive care medicine with Clinical trial. While Drug development is the focus of the journal, it also provided insights into the studies of Disease and Pharmaceutical industry.

The most cited articles from the last journal are:

  • Artificial intelligence in drug discovery and development. (40 citations)
  • Potential SARS-CoV-2 main protease inhibitors. (18 citations)
  • Expanded Access Programs, compassionate drug Use, and Emergency Use Authorizations during the COVID-19 pandemic. (17 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Drug Discovery Today (based on the number of publications) are:

  • Kathryn Senior (50 papers) absent at the last edition,
  • Raymond C Rowe (42 papers) absent at the last edition,
  • Paul Edwards (38 papers) absent at the last edition,
  • Rebecca N Lawrence (34 papers) absent at the last edition,
  • Martina Habeck (33 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Drug Discovery Today (based on the number of publications) are:

  • AstraZeneca (139 papers) published 7 papers at the last edition, 3 more than at the previous edition,
  • Pfizer (104 papers) published 4 papers at the last edition, 3 more than at the previous edition,
  • GlaxoSmithKline (94 papers) published 2 papers at the last edition,
  • Novartis (67 papers) published 7 papers at the last edition, 5 more than at the previous edition,
  • National Institutes of Health (58 papers) published 6 papers at the last edition, 5 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 11.49% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 12.28% were posted by at least one author from the top 10 institutions publishing in the journal. Another 7.02% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 19.65% of all publications and 61.05% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Top Publications

  • Targeting CDK2 in cancer: challenges and opportunities for therapy

    Solomon Tadesse;Abel T. Anshabo;Neil Portman;Elgene Lim

    (2020)
    200 Citations
  • Comparison of DNA and mRNA vaccines against cancer.

    Zohreh Jahanafrooz;Behzad Baradaran;Jafar Mosafer;Mahmoud Hashemzaei

    (2020)
    139 Citations
  • Immune checkpoint inhibitors: a promising anticancer therapy

    Sima Singh;Daniel Hassan;Hibah M. Aldawsari;Nagashekhara Molugulu

    (2020)
    133 Citations
  • Advanced machine-learning techniques in drug discovery.

    Moe Elbadawi;Simon Gaisford;Simon Gaisford;Abdul W. Basit;Abdul W. Basit

    (2021)
    128 Citations
  • Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects.

    Sepideh Mirzaei;Mohammad Hossein Gholami;Farid Hashemi;Amirhossein Zabolian

    (2021)
    125 Citations
  • Theranostic application of nanoemulsions in chemotherapy.

    Bapi Gorain;Hira Choudhury;Anroop B. Nair;Sunil K. Dubey

    (2020)
    113 Citations
  • Long noncoding RNAs (lncRNAs) in pancreatic cancer progression.

    (2022)
    88 Citations
  • Recent advances in targeted nanomedicine as promising antitumor therapeutics.

    Siddhanth Hejmady;Rajesh Pradhan;Amit Alexander;Mukta Agrawal

    (2020)
    87 Citations
  • Nanovehicles for co-delivery of anticancer agents.

    Mahdi Zeinali;Soheil Abbaspour-Ravasjani;Marjan Ghorbani;Afshin Babazadeh

    (2020)
    86 Citations
  • The clinical significance of 4D printing.

    (2022)
    84 Citations

Related Online Degrees & Career Pathways

For those interested in Medicine in the USA, exploring related online degrees and career pathways can provide diverse options beyond a traditional MD. Nursing, for example, offers a valuable route with flexible options such as the lpn accelerated program, which allows students to quickly enter the healthcare field while gaining essential patient care skills.

For advanced nursing professionals, pursuing the cheapest online nursing phd programs can enhance career opportunities in research, education, and leadership roles, often with reduced financial barriers due to affordability and online accessibility.

In addition, administration and support roles are growing in demand. Online programs in medical billing and coding provide essential skills for managing healthcare records and reimbursements, offering a reliable career path complementary to clinical roles.

Students with a background in life sciences should also consider the broad range of biology major careers available, many of which intersect with medicine, such as biomedical research, pharmacology, and public health. These pathways highlight the flexibility and variety within health-related education and employment.

Best Scientists Contributing to This Journal